5-(m-benzyloxy)benzylidenebarbituric acid | 154021-69-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(m-benzyloxy)benzylidenebarbituric acid
• 英文别名: 5-(3-(benzyloxy)benzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione；PX075245；Fchcvwpsaxphgn-uhfffaoysa-；5-[(3-phenylmethoxyphenyl)methylidene]-1,3-diazinane-2,4,6-trione
• CAS: 154021-69-9
• 化学式: C₁₈H₁₄N₂O₄
• 分子量: 322.32
• InChiKey: FCHCVWPSAXPHGN-UHFFFAOYSA-N

物化性质

• 密度：
  1.340±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  84.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(m-benzyloxy)benzylidenebarbituric acid 在 sodium tetrahydroborate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以82%的产率得到5-[[3-(苯基甲氧基)苯基]甲基]-1,3-二嗪农-2,4,6-三酮
  参考文献：
  名称：

  Tzeng, Cherng-Chyi; Panzica, Raymond P.; Naguib, Fardos N.M., Journal of Heterocyclic Chemistry, 1993, vol. 30, # 5, p. 1399 - 1404

  摘要：

  DOI：
• 作为产物：
  描述：

  间羟基苯甲醛 在 potassium carbonate 作用下， 以 乙醇 、 水 、 乙腈 为溶剂， 反应 3.08h， 生成 5-(m-benzyloxy)benzylidenebarbituric acid
  参考文献：
  名称：

  피부미백, 항산화 및 ＰＰＡＲ 활성을 갖는 신규 화합물 및 이의 의학적 용도

  摘要：

  本发明涉及具有皮肤美白、抗氧化和PPAR活性的新化合物及其医学用途，根据本发明的化合物具有抑制酪氨酸酶的皮肤美白活性，因此可用于皮肤美白药物组合物或化妆品中，具有抗氧化活性，因此可用于预防或治疗皮肤老化等，另外，由于具有PPAR活性，特别是具有PPARα和PPARγ活性，因此可用作预防和治疗肥胖、代谢性疾病或心血管疾病的药物组合物或保健食品。

  公开号：

  KR101677122B1

文献信息

• NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREFOR
  申请人：Chung Hae Young

  公开号：US20140023603A1

  公开（公告）日：2014-01-23

  Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  提供了一种具有美白皮肤、抗氧化和PPAR活性的新化合物及其医疗用途，该化合物具有美白皮肤的活性，可抑制酪氨酸酶，因此适用于用于美白皮肤的药物组合物或化妆品；具有抗氧化活性，因此适用于预防和治疗皮肤老化；具有PPAR活性，特别是PPARα和PPARγ活性，因此适用于用于预防和治疗肥胖、代谢性疾病或心血管疾病的药物组合物或保健食品。
• [EN] PYRIMIDINE DERIVATIVES FOR USE AS ANTIBIOTICS<br/>[FR] DÉRIVÉS DE PYRIMIDINE À UTILISER EN TANT QU'ANTIBIOTIQUES
  申请人：UNIV ASTON

  公开号：WO2010136804A1

  公开（公告）日：2010-12-02

  The invention provides a compound of formula (i): wherein R1 and R2 are independently selected from hydrogen, methyl, ethyl, propyl and butyl; R3 is selected from substituted or unsubstituted anthryl, substituted or unsubstituted pyrenyl, substituted or unsubstituted carbazolyl, substituted or unsubstituted imidazolyl, substituted or unsubstituted phenanthrenyl, substituted or unsubstituted fluorenyl, substituted or unsubstituted 1-naphthyl, substituted 2-naphthyl, and substituted phenyl, and X1 and X3 are independently selected from O or S, and X2 is O; and L is selected from C1 to C3 alkyl, C1 to C3 alkoxyl, C2 or C3 alkenyl, and C2 or C3 alkynyl; and the bond connecting L to the ring is a single or a double bond; wherein when the bond connecting L to the pyrimidine ring is a double bond, the substituted phenyl is not a monosubstituted 2- or 4- halobenzene; and wherein the substituted phenyl is not a toluene, anisole, phenol, dimethylaniline, guaiacol, or benzyl phenyl ether moiety; or a pharmaceutically, or veterinarily, acceptable derivative thereof. The use of such compounds as medicaments, in particular as antibiotics, specifically antibiotics for the inhibition of bacterial DHODase is also described, as are compositions (pharmaceutical and anti-infective) containing the compositions, articles or surfaces coated impregnated with the anti- infective compositions. Finally, the invention provides methods for the treatment of a disease and methods for preventing bacterial transmission including the compounds of formula 1.

  这项发明提供了一个式（i）的化合物：其中R1和R2分别选自氢、甲基、乙基、丙基和丁基；R3选自取代或未取代的蒽基、取代或未取代的芘基、取代或未取代的咔唑基、取代或未取代的咪唑基、取代或未取代的菲基、取代或未取代的芴基、取代或未取代的1-萘基、取代的2-萘基和取代的苯基，X1和X3分别选自O或S，X2为O；L选自C1到C3烷基、C1到C3烷氧基、C2或C3烯基和C2或C3炔基；连接L到环的键为单键或双键；当连接L到嘧啶环的键为双键时，取代的苯基不是单取代的2-或4-卤苯；取代的苯基不是甲苯、甲酚、二甲基苯胺、愈创木酚或苄基苯醚基团；或其药学或兽医学上可接受的衍生物。还描述了这些化合物作为药物的用途，特别是作为抗生素，特别是用于抑制细菌DHODase的抗生素，以及含有这些化合物的组合物（药用和抗感染），涂有抗感染组合物的物品或表面。最后，该发明提供了一种治疗疾病的方法和预防细菌传播的方法，包括式1的化合物。
• NOVEL COMPOUND HAVING SKIN-WHITENING, ANTI-OXIDIZING AND PPAR ACTIVITIES AND MEDICAL USE THEREOF
  申请人：Pusan National University Industry-University Cooperation Foundation

  公开号：US20160102065A1

  公开（公告）日：2016-04-14

  Provided are a novel compound having skin-whitening, anti-oxidizing and PPAR activities and a medical use thereof, and the compound has skin-whitening activities for the suppression of tyrosinase, and accordingly, is useful for use in skin-whitening pharmaceutical composition or cosmetic products; has anti-oxidant activities, and accordingly, is useful for the prevention and treatment of skin-aging; and has PPAR activities, and in particular, PPARα and PPARγ activities, and accordingly, is useful for use in pharmaceutical compositions or health foods which are effective for the prevention and treatment of obesity, metabolic disease, or cardiovascular disease.

  提供了一种具有美白、抗氧化和PPAR活性的新化合物及其医疗用途。该化合物具有抑制酪氨酸酶的美白活性，因此可用于美白药物组合物或化妆品产品；具有抗氧化活性，因此可用于预防和治疗皮肤老化；具有PPAR活性，特别是PPARα和PPARγ活性，因此可用于有效预防和治疗肥胖症、代谢疾病或心血管疾病的药物组合物或保健食品。
• Exploring new inhibitors of Plasmodium falciparum purine nucleoside phosphorylase
  作者：Huaqing Cui、Gian Filippo Ruda、Juana Carrero-Lérida、Luis M. Ruiz-Pérez、Ian H. Gilbert、Dolores González-Pacanowska

  DOI：10.1016/j.ejmech.2010.08.026

  日期：2010.11

  Plasmodium falciparum purine nucleoside phosphorylase (PfPNP) has a central role in purine salvage and inhibitors of the enzyme have been shown to have antiplasmodial activity. The enzyme preferentially uses inosine as substrate (K-m = 51 mu M, k(cat)/K-m = 7.4 x 10(4) M-1 s(-1)), but can also use uridine, albeit less efficiently (K-m = 85 mu M, k(cat)/K-m = 306 M-1 s(-1)). In an effort to identify new PfPNP inhibitors, two series of compounds were prepared. Series 1 was based on known human uridine phosphorylase inhibitors whilst series 2 was uracil equivalents of purine-based PNP transition state inhibitors. These two series of compounds were assayed for inhibition of both PfPNP activity and growth of P. falciparum. The transition state analogues were found to be moderate inhibitors of PfPNP (most potent compound, K-i = 6 mu M). (C) 2010 Elsevier Masson SAS. All rights reserved.
• BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
  申请人：Novuspharma S.p.A.

  公开号：EP1305026B1

  公开（公告）日：2009-05-13